Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Invivyd ( (IVVD) ) has issued an update.
On May 12, 2025, Invivyd announced a new discovery program aimed at developing a monoclonal antibody treatment for measles. This initiative addresses the increasing risk of measles outbreaks due to declining vaccination rates, with over 20 million unvaccinated individuals in the U.S. The program aims to identify a preclinical candidate by the end of 2025, potentially offering a critical therapeutic option for those unable to receive vaccines. The announcement underscores Invivyd’s strategy to leverage its expertise in antibody discovery to combat viral infectious diseases, positioning the company as a key player in addressing unmet medical needs related to measles.
The most recent analyst rating on (IVVD) stock is a Buy with a $15.0000 price target. To see the full list of analyst forecasts on Invivyd stock, see the IVVD Stock Forecast page.
Spark’s Take on IVVD Stock
According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.
Invivyd’s overall stock score reflects significant financial and technical weaknesses, marked by ongoing losses and bearish trends. While recent corporate developments offer a glimpse of potential strategic improvement, these are overshadowed by the current financial instability and weak market sentiment.
To see Spark’s full report on IVVD stock, click here.
More about Invivyd
Invivyd, Inc. is a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, starting with SARS-CoV-2. The company utilizes a proprietary integrated technology platform to develop best-in-class monoclonal antibodies.
Average Trading Volume: 3,216,584
Technical Sentiment Signal: Sell
Current Market Cap: $77.51M
Learn more about IVVD stock on TipRanks’ Stock Analysis page.